BeOne Medicines (NASDAQ:ONC) Price Target Raised to $425.00

Key Points

• Royal Bank of Canada raised its price target on BeOne Medicines to $425 (from $423) with an "outperform" rating, implying about a 35% upside, while analyst views are mixed — MarketBeat's consensus target is $391 with a "Moderate Buy" and firms like Jefferies have cut their rating and target to $290.
• BeOne reported strong Q1 revenue of $1.51 billion and issued FY‑2026 revenue guidance of roughly $6.3–$6.5 billion, but its Q1 EPS missed materially at $0.25 versus a $0.73 consensus, a near‑term negative for the stock.
• Shares traded around $314.26 with a market cap of $34.48 billion and a P/E of 124.9; insiders own about 6.62% of the stock and institutional investors hold roughly 48.55%.

BeOne Medicines (NASDAQ:ONC - Get Free Report) had its price objective boosted by research analysts at Royal Bank Of Canada from $423.00 to $425.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Royal Bank Of Canada's target price would indicate a potential upside of 35.24% from the company's previous close.

A number of other research firms have also commented on ONC. Guggenheim raised their price target on shares of BeOne Medicines from $410.00 to $420.00 and gave the stock a "buy" rating in a research report on Thursday. Jefferies Financial Group lowered shares of BeOne Medicines from a "buy" rating to a "hold" rating and lowered their price target for the stock from $420.00 to $290.00 in a research report on Monday, March 16th. Wall Street Zen lowered shares of BeOne Medicines from a "strong-buy" rating to a "buy" rating in a research report on Saturday, February 28th. Morgan Stanley reaffirmed an "overweight" rating and set a $395.00 price target on shares of BeOne Medicines in a research report on Thursday. Finally, Barclays raised their price target on shares of BeOne Medicines from $405.00 to $409.00 and gave the stock an "overweight" rating in a research report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $391.00.

BeOne Medicines Stock Performance

Shares of ONC traded up $0.94 during trading hours on Thursday, hitting $314.26. The company had a trading volume of 196,388 shares, compared to its average volume of 251,982. The firm has a market cap of $34.48 billion, a price-to-earnings ratio of 124.90 and a beta of 0.50. The business has a fifty day moving average of $302.44 and a 200-day moving average of $322.00. BeOne Medicines has a 12 month low of $218.31 and a 12 month high of $385.22. The company has a quick ratio of 3.08, a current ratio of 3.41 and a debt-to-equity ratio of 0.22.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last issued its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a net margin of 5.37% and a return on equity of 10.70%. The company had revenue of $1.51 billion for the quarter. Equities analysts anticipate that BeOne Medicines will post 5.44 EPS for the current fiscal year.

Insider Transactions at BeOne Medicines

In other BeOne Medicines news, SVP Chan Henry Lee sold 332 shares of the stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $311.59, for a total transaction of $103,447.88. Following the sale, the senior vice president directly owned 318,370 shares in the company, valued at $99,200,908.30. This represents a 0.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.62% of the stock is owned by insiders.

Institutional Investors Weigh In On BeOne Medicines

A number of large investors have recently bought and sold shares of the company. Fiera Capital Corp boosted its position in BeOne Medicines by 20.1% during the 3rd quarter. Fiera Capital Corp now owns 25,117 shares of the company's stock worth $8,557,000 after buying an additional 4,205 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in BeOne Medicines by 1,019.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 42,816 shares of the company's stock worth $14,587,000 after buying an additional 38,992 shares during the period. Clear Harbor Asset Management LLC acquired a new stake in BeOne Medicines during the 3rd quarter worth approximately $548,000. AIA Group Ltd boosted its position in BeOne Medicines by 31.4% during the 3rd quarter. AIA Group Ltd now owns 32,303 shares of the company's stock worth $11,006,000 after buying an additional 7,716 shares during the period. Finally, Slow Capital Inc. boosted its position in BeOne Medicines by 51.5% during the 4th quarter. Slow Capital Inc. now owns 27,301 shares of the company's stock worth $8,294,000 after buying an additional 9,280 shares during the period. 48.55% of the stock is currently owned by institutional investors and hedge funds.

Key BeOne Medicines News

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Truist reaffirmed a "buy" and nudged its price target to $413 (from $411), implying roughly a 32% upside from current levels. Read More.
• Positive Sentiment: Wells Fargo upgraded ONC to "strong-buy," adding institutional momentum that can support the stock. Read More.
• Positive Sentiment: Market coverage noted a post-quarter surge after what reporters described as a "robust" Q1 performance — headlines and positive sentiment helped lift buyer interest. Read More.
• Neutral Sentiment: BeOne reported Q1 revenue of $1.51 billion and issued FY‑2026 revenue guidance of about $6.3–$6.5 billion, essentially in line with consensus — supportive for top-line outlook but not a clear catalyst. Read More.
• Neutral Sentiment: Management's Q1 results presentation and the earnings‑call materials are available for detail on pipeline and margins; these will matter for longer‑term sentiment. Read More.
• Negative Sentiment: Earnings per share missed materially — $0.25 reported vs. $0.73 consensus — a clear near-term negative that likely pressured the stock despite healthy revenue. Read More.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.